Personalis rises on expanded Medicare coverage for cancer test

Shares of cancer diagnostics firm Personalis PSNL.O rise 6.8% to $6.45 premarket

Co says Medicare coverage for its NeXT Personal cancer test has been expanded to monitor patients with late-stage solid tumors receiving immunotherapy

The test tracks tiny traces of cancer left in the body, helping doctors assess whether immunotherapy is working - PSNL

PSNL says decision was based on a study showing the test could track immunotherapy response and forecast outcomes earlier than standard scans

Expansion follows earlier Medicare coverage for the test to monitor lung cancer recurrence

Medicare is the U.S. government health insurance program for people aged 65 and older

As of last close, PSNL down 24.1% YTD